Innovation in
Drug Delivery
Using Energy Based Systems
At Focal Medical, we’re applying our sophisticated technology platforms to revolutionize the way drugs are delivered to improve patient healthcare outcomes. Our goal is to reduce side effects, maximize the potency of drug therapy and yield better outcomes for patients.
intro
Precision drug targeting is more important than ever:
- In cases where a single organ is the target of treatment, systemic drug delivery may result in only limited exposure of the target organ to the therapeutic agent.
- Drugs, when delivered systemically, may have negative effects on the whole body, these effects may limit the tolerable drug dose.
To address these shortcomings, Focal Medical’s products use a targeted energy field for the precision delivery of drugs to their intended location.
Utilizing our approach, we believe drug therapy can deliver dramatically better health outcomes, enabling the treatment of otherwise intractable diseases.
technology
New Hope for Pancreatic Cancer Therapy
Our first program pursues one of cancer’s most significant unmet medical need — locally advanced pancreatic adenocarcinoma that is unremovable at diagnosis. Our IND has been cleared by the FDA and we expect to initiate our first clinical trial in 2024. Our confidence in this program is based on our extensive safety and tolerability preclinical evidence in small and large animal models, our unprecedented preclinical efficacy results from studies conducted at University of North Carolina – Chapel Hill, and the significant unmet medical need which pancreatic patients face.
Benefits
Our technology establishes an electric field at the delivery site, and actively delivers drug molecules precisely and specifically into target cells utilizing non-circulatory pathways.
Utilizes non-blood pathways to actively drive drug through barriers and resistance mechanisms directly to target cells.
Actively moves drug across the cellular wall, enhancing concentration and viability at its target site.
Reduces exposure of non-diseased tissue and associated unwanted side effects.
meet the team
Our veteran team bridges the gap between biotechnology and medical device manufacturing, with experience in both startups and established companies. Our technology emerged from the labs of a distinguished surgical oncologist and a renowned chemical engineer and entrepreneur at the University of North Carolina. In addition to Series A funding, we have secured several grants from the National Institutes of Health.
news & updates
Cary, North Carolina — Focal Medical, Inc., (“Focal”) a privately held biopharmaceutical company developing a…
Ness Bermingham, Ph.D. Khosla Ventures partner and Intellia Therapeutics founder, joins Board. Advance of IOP…
ACT-IOP-003 is an implantable iontophoretic product designed to safely achieve high concentration of gemcitabine in…
Developed a laparoscopic surgical technique to enable the minimally invasive implantation of ACT-IOP-003 device onto…
Successful completion of development of a precision therapeutic system designed to safely achieve high concentration…
Trial & Enrollment Details Cary, NC and Roanoke, VA, May 04, 2023 — Focal…
RALEIGH, N.C. (November 1, 2022): Focal Medical, Inc. (formerly Advanced Chemotherapy Technologies, Inc.), a privately held,…
This investment is in addition to the previously announced Series A investment of $5.5 million…
Focal Medical, Inc.
2301 Stonehenge Drive, STE 115
Raleigh NC 27615
(919) 377 2283
Focal Medical Copyright 2022-2024 | Focal Medical is an equal opportunity employer
Terms of service – Privacy policy – Other policies